CoChat
Sign Up
Cited by 89Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsAtrial Fibrillation Management and Outcomes

Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER ® , RE-COVER™ II, and RE-MEDY™

Goldhaber, Samuel Z, Eriksson, Henry, Kakkar, Ajay, Schellong, Sebastian, Feuring, Martin, Fraessdorf, Mandy, Kreuzer, Joerg, Schueler, Elke +1 more·2016·Vascular Medicine
DOI 10.1177/1358863x16668588
Open this paper in CoChat — free account

Abstract

It is unclear whether thrombophilia causes resistance to anticoagulant therapy. Post hoc analyses of data from RE-COVER ® , RE-COVER ™ II, and RE-MEDY ™ were performed to compare dabigatran etexilate with warfarin for the treatment and prevention of venous thromboembolism (VTE) in patients with thrombophilia or antiphospholipid antibody syndrome (APS). There were no significant differences in symptomatic VTE/VTE-related deaths between dabigatran etexilate and warfarin in patients with or without thrombophilia. All bleeding event categories were less frequent with dabigatran etexilate than with warfarin, regardless of whether patients had thrombophilia, no thrombophilia, or were not tested. However, these differences did not reach significance in every group. In patients with APS, there was no significant difference in VTE/VTE-related deaths between the two treatment arms. Rates of bleeding events tended to be lower with dabigatran etexilate than with warfarin, reaching statistical significance for any bleeding event. In conclusion, the efficacy and safety of dabigatran etexilate were not significantly affected by the presence of thrombophilia or APS. ClinicalTrials.gov RECOVER IDENTIFIER NCT00291330; RECOVER II IDENTIFIER NCT00680186; RE-MEDY IDENTIFIER NCT00329238.

Integrity signals

Registry

Crossref · 10.1177/1358863x16668588

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a post-hoc analysis of antiphospholipid syndrome patients in three RCTs of dabigatran versus warfarin and one RCT of rivaroxaban versus warfarin in venous thrombotic antiphospholipid syndrome, there were no differences in outcomes between direct oral anticoagulants and vitamin K antagonists for venous thrombosis.

    “In a post-hoc analysis of patients with APS included in three RCTs of dabigatran versus warfarin,26 and in one RCT of rivaroxaban versus warfarin in patients with venous thrombotic APS,27 there were no differences in outcomes between treatment with DOACs and VKA for venous thrombosis”

    From EULAR recommendations for the management of antiphospholipid syndrome in adults (2019) · cites this paper as [26]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Goldhaber, S. Z., Eriksson, H., Kakkar, A., Schellong, S., Feuring, M., Fraessdorf, M., Kreuzer, J., Schueler, E., & Schulman, S.
Affiliations
  • Brigham and Women's Hospital (US)
  • Sahlgrenska University Hospital (SE)
  • Thrombosis Research Institute (GB)
  • Krankenhaus Dresden-Friedrichstadt (DE)
  • Boehringer Ingelheim (Germany) (DE)
  • Accovion GmbH, Eschborn, Germany
  • Thrombosis and Atherosclerosis Research Institute (CA)
Corresponding author
Goldhaber, Samuel Z
ORCID
Venue
Vascular Medicine
Publisher
SAGE Publications
Published
2016-11-02
Volume
21
Issue
6
Pages
506-514
ISSN
  • 1358-863X (ISSN-L)
  • 1477-0377
DOI
10.1177/1358863x16668588
OpenAlex
W2548912661
Cited by
89
References
3
Citations by year
2026: 3 · 2025: 5 · 2024: 12 · 2023: 10 · 2022: 14 · 2021: 9 · 2020: 16 · 2019: 13 · 2018: 6 · 2017: 1
FWCI
6.60
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Vascular Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bayer Fund
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
dabigatran etexilate, warfarin, acute venous thromboembolism, thrombophilia, antiphospholipid syndrome, direct oral anticoagulants, bleeding events
MeSH terms
Dabigatran, Acute Disease, Adult, Aged, Anticoagulants, Antithrombins, Female, Fibrinolytic Agents, Hemorrhage, Humans, Male, Middle Aged, Risk Factors, Time Factors, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Thrombophilia, Kaplan-Meier Estimate, Venous Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review